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Patients with cholestasis-lymphedema syndrome (CLS) suffer severe neonatal cholestasis that usually lessens during
early childhood and becomes episodic; they also develop chronic severe lymphedema. The genetic cause of CLS is
unknown. We performed a genome screen, using DNA from eight Norwegian patients with CLS and from seven
unaffected relatives, all from an extended pedigree. Regions potentially shared identical by descent in patients were
further characterized in a larger set of Norwegian patients. The patients manifest extensive allele and haplotype
sharing over the 6.6-cM D15S979–D15S652 region: 30 (83.3%) of 36 chromosomes of affected individuals carry
a six-marker haplotype not found on any of the 32 nontransmitted parental chromosomes. All Norwegian patients
with CLS are likely homozygous for the same disease mutation, inherited from a shared ancestor.
Four proteins disrupted in forms of hereditary cholesta-
sis have recently been identified. Lesions in JAG1, a li-
gand for the NOTCH1 receptor, underlie Alagille syn-
drome (MIM 118450) (Li et al. 1997; Oda et al. 1997).
FIC1, a widely expressed P-type ATPase of unknown
function, is altered in progressive familial intrahepatic
cholestasis type 1 (PFIC1 [MIM 211600]) and in many
cases of benign recurrent intrahepatic cholestasis, an ep-
isodic disorder (BRIC [MIM 243300]) (Bull et al. 1998).
BSEP, a bile-acid transporter, is defective in progressive
familial intrahepatic cholestasis type 2 (PFIC2 [MIM
601847]) (Gerloff et al. 1998; Strautnieks et al. 1998;
Green et al. 2000). Defects in MDR3, a phospholipid
flippase, are responsible for progressive familial intra-
hepatic cholestasis type 3 (PFIC3 [MIM 602347]) (de
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Vree et al. 1998; Jacquemin et al. 1999). The genetic
basis of other hereditary cholestatic disorders remains
to be elucidated (Knisely 2000). Among these is chole-
stasis-lymphedema syndrome (CLS).
Patients with CLS, or Aagenaes syndrome (MIM
214900), suffer severe neonatal cholestasis with hy-
perbilirubinemia, increased serum concentrations of bile
acids, and giant-cell transformation of hepatocytes (Aa-
genaes et al. 1968, 1970; Aagenaes 1998). In most pa-
tients, manifestations of liver disease lessen during early
childhood and become episodic, as in BRIC. In a few
patients, however, the course of cholestasis resembles
that in PFIC, with cirrhosis and death in childhood;
other patients develop cirrhosis as adults. CLS is distinct
from other forms of cholestatic liver disease in that pa-
tients manifest lymphedema, either at birth or during
childhood; lymphedema becomes chronic and severe,
mainly affecting the lower extremities but also the hands,
scrotum, and periorbital soft tissues. Later in life, lym-
phedema can affect the small intestine and the thoracic
soft tissue, with chylothorax (Ø. Aagenaes, unpublished
data). Lymph vessels in patients with CLS are hypo-
plastic (Aagenaes et al. 1970).
Other forms of hereditary lymphedema, with or with-
out other associated disease, exist; progress has recently
been made in molecular genetic characterization of two
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Figure 1 Pedigree 1. Known and probable ancestral relationships between members are shown. Individuals whose DNA was included
in the genome screen are indicated by an “X.” The affected sib pair in the lower-left corner was identified subsequent to performance of the
genome screen.
of them. Some patients with autosomal dominant pri-
mary lymphedema (MIM 153100) carry alterations in
FLT4 (vascular endothelial growth factor C receptor-3);
evidence also supports locus heterogeneity for this dis-
order (Ferrell et al. 1998; Witte et al. 1998; Evans et al.
1999; Karkkainen et al. 2000). A locus for lymphedema-
distichiasis syndrome (MIM 153200) has been mapped
to chromosome 16q24 (Mangion et al. 1999). Henne-
kam syndrome (MIM 235510) demonstrates similari-
ties to CLS, including autosomal recessive inheritance,
lower-extremity lymphedema, and intestinal lymphan-
giectasia (Hennekam et al. 1989). Neither the Henne-
kam syndrome locus nor loci altered in other hereditary
lymphedemas have been mapped. CLS is the only he-
reditary lymphedema associated with cholestasis.
CLS was first described in a Norwegian pedigree (fig.
1), in which the disease demonstrates autosomal reces-
sive inheritance (Aagenaes et al. 1968; Aagenaes 1998).
Most reported cases have occurred in individuals ofNor-
wegian descent, although CLS occurs as well in people
of other ancestries (Sharp and Krivit 1971; Aagenaes
1974; Vajro et al. 1984; Pawlowska et al. 1994, 1995;
Morris et al. 1997; Aagenaes 1998). Most Norwegian
patients are from a single region in southwestern Nor-
way and are known or likely descendants of a founding
couple born circa 1570 (fig. 1).
Plans for this study were initiated by a group of pa-
tients with CLS and their relatives. Informed consent of
participants was obtained using established protocols at
the University of Oslo. This study was also approved by
the Committee on Human Research at the University of
California San Francisco. Blood was collected fromNor-
wegian patients who met diagnostic criteria for CLS
(Aagenaes 1998) and from their available unaffected
parents.
To localize the CLS gene, we performed a whole-ge-
nome screen using DNA from members of pedigree 1
(fig. 1). Standard linkage analysis was not feasible be-
cause of the complex pedigree structure and lack of sam-
ples from many members. We therefore screened for ge-
996 Am. J. Hum. Genet. 67:994–999, 2000
Figure 2 Pedigree 2. Asterisks (*) indicate individuals from
whom we obtained DNA.
nomic regions potentially shared identical by descent
(IBD) by several patients. We genotyped eight affected
members of the pedigree—including two sib pairs and
one first-cousin pair—and seven unaffected relatives (fig.
1), with 385 autosomal microsatellite markers, most of
which were from the PE Biosystems Linkage Mapping
Set, version 2. We typed two additional markers in the
FIC1 region. DNA was amplified in a GeneAmp 9700
apparatus (PE Biosystems), and reaction products were
electrophoresed on a 377 or 3700 apparatus (PE Bio-
systems). Some follow-up genotyping in candidate re-
gions was performed using radioactively labeled primers,
as described elsewhere (Bull et al. 1999). All genotypes
were determined independently by two observers. When
possible, allele sizes were assigned relative to those re-
ported or apparent in control sample 1347-2 (Centre
d’E´tude du Polymorphisme Humaine).
Under the assumptions of an autosomal recessive
mode of inheritance for CLS and a single ancestral mu-
tation in this pedigree, siblings should be IBD for both
copies of the chromosomal region containing the disease
gene, and cousins should be IBD for the copy of the
region inherited from their shared grandparents. There-
fore, regions consistent with potential IBD inheritance
in all three of the two affected sib pairs and the affected
cousin pair were considered to be promising CLS can-
didate regions. Fifty-seven genomic intervals, totaling
25% of the genome, were potentially shared IBD in each
of the three pairs—that is, there were no apparent re-
combinations that would exclude such sharing.
To prioritize these 57 intervals for further analysis, we
examined data from all eight patients, to identify po-
tential sharing between the more distantly related chro-
mosomes. Intervals containing a marker for which a sin-
gle allele occurred with high frequency on chromosomes
in affected individuals, as well as those in which a
two-marker haplotype was shared by a number of chro-
mosomes present in affected individuals, were consid-
ered to be particularly promising. Intervals of compar-
atively long genetic length and/or containing one or
more markers were weighted as being more promising
than those spanning very short genetic intervals and/or
containing no typed markers. We judged 19 of the 57
potential candidate regions to be particularly promising.
We also evaluated regions containing genes mutated
in forms of hereditary cholestasis or lymphedema. Data
for the intervals containing BSEP, MDR3, FIC1, JAG1,
and the lymphedema-distichiasis syndrome locus were
inconsistent with potential IBD sharing in the three
close-relative pairs; these intervals were not studied fur-
ther. The region containing FLT4 was consistent with
IBD sharing in the three close-relative pairs, but there
was no evidence of allele or haplotype sharing of the
region among chromosomes in affected individuals, in
either initial or follow-up studies.
We further characterized the most promising regions,
to distinguish the CLS region from the other, “false pos-
itive” regions, through genotyping of additional sam-
ples, including a second, recently identified Norwegian
family containing an affected sib pair (pedigree 2; fig.
2); where necessary, we also typed these samples, as well
as those included in the genome screen, for additional
markers within the intervals.
The 21.7-cMD15S205–D15S130 interval was among
the most interesting regions, on the basis of results from
the genome screen; however, it was not unequivocally
identifiable as the CLS region until the follow-up analysis
was performed. In the initial screen, 15 of the 16 copies
of chromosome 15 present in affected individuals car-
ried an identical allele of marker D15S127, which lies
between D15S205 and D15S130. For only one other
marker in the genome screen, D3S1565, did this many
disease chromosomes share a single allele. Suggestive ev-
idence for some haplotype sharing over the D15S205–
D15S130 interval was also obtained from the genome
screen.
Eleven microsatellite markers within the D15S205–
D15S130 region were typed in a total of 23 Norwegian
patients with CLS and in their unaffected relatives. These
23 patients include 17 affected members of pedigree 1,
including a recently identified additional affected sib pair
(fig. 1), as well as 3 affected members from pedigree
2 (fig. 2) and 3 Norwegian patients with CLS who are
the only known affected individuals in their families.
We focused particularly on typing of markers near
D15S127. Table 1 summarizes the results of this work;
for each of the 11 markers, the allele most enriched on
chromosomes of patients, compared with nontransmit-
ted parental chromosomes, is shown, as are the per-
centages of affected and nontransmitted chromosomes
that carry this allele. (For this analysis, data from one
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Table 1
Allele Sharing in the D15S205–D15S130 Region
MARKERa ALLELEb
PROPROTION OF CHROMOSOMES
(%)
CLSc NTd
D15S205 158 15.8 0
D15S655 234 34.2 21.9
D15S979 157 15.8 0
D15S996 196 92.1 44.4
D15S127 119 86.8 22.6
FESe 16 94.7 50.0
IP15M9 69 100 43.3
D15S158 95 94.7 7.1
D15S963 271 100 56.3
D15S652 305 32.9 18.3
D15S130 288 34.2 27.6
NOTE.—Data from 36–38 of the 38 affected chromosomes included
were available for each marker, as were data from 27–32 of the 32
nontransmitted chromosomes.
a Listed in order from centromere to telomere.
b Allele most enriched on copies of the region present in affected
individuals, relative to the nontransmitted chromosomes of patients’
parents (alleles rarely present on disease chromosomes are not
included).
c Percentage of chromosomes present in affected individuals who
carry this enriched allele.
d Percentage of nontransmitted chromosomes carrying this allele.
e Alleles present in 1347-2 were arbitrarily designated “24-20.”
member of each affected sib pair are excluded; when
two sibs differ, because of recombination, in the allele
for a given marker that is inherited from a parent, each
allele is counted as 0.5 copies.) To a striking degree,
affected chromosomes share alleles in this region, par-
ticularly at the markers fromD15S996 to D15S963; for
five of these six markers, 190% of the affected chro-
mosomes carry the same allele. A disease-associatedhap-
lotype can be defined for this six-marker interval. These
results indicate that the CLS gene lies within the 6.6-cM
D15S979–D15S652 interval (genetic distances are from
the Center for Medical Genetics,MarshfieldMedical Re-
search Foundation map.)
Some alleles present on the shared disease haplotype
are also relatively common on the nontransmitted chro-
mosomes; many of the individuals studied are known to
be at least distantly related; and no genetic distance be-
tween D15S996 and D15S963 is currently detectable.
Therefore, to exclude the possibility that background,
rather than disease-associated, linkage disequilibrium
(LD) makes a major contribution to sharing of this hap-
lotype, we determined the frequency of the six-marker
haplotype on affected and nontransmitted chromo-
somes. The full haplotype is present on 30 (83.3%) of
36 affected chromosomes for which complete, phase-
known data are available (again, one member of each
sib pair was excluded from this analysis). In contrast,
none of the 32 nontransmitted chromosomes carried the
full haplotype. This finding confirms that the haplotype
sharing in this region is due to the presence of a disease
mutation rather than to non–disease-associated LD.
Data from each of the four affected sib pairs are con-
sistent with linkage to this region, under an autosomal
recessive model; recombination events in two of these
four families place the CLS gene within the D15S979–
D15S652 interval, the same interval in which haplotype
analysis places the gene.
On all but two of the affected chromosomes, alleles
of the six-marker shared D15S996–D15S963 haplo-
type occur at four or more contiguous markers; the two
chromosomes on which alleles of the disease haplotype
occur at fewer than four contiguous markers are inmem-
bers of pedigree 1. These findings indicate that all of the
Norwegian patients with CLS in our study carry the
same founder mutation and that all CLS cases inNorway
are likely due to this mutation.
We used several criteria to evaluate the data from our
genome screen; in retrospect, the data on sharing of al-
leles at single markers, rather than on sharing of two-
marker haplotypes, most clearly highlighted the candi-
date region in the results of the genome screen. Because
dramatic haplotype sharing in the CLS region extends
over !7 cM, either a higher-density marker set or a pa-
tient sample size large enough to make the application
of statistical approaches to data analysis appropriate
would have been needed for clear identification of the
shared haplotype in the genome screen. However, shar-
ing of a single allele at D15S127 on 15 of the 16 chro-
mosomes present in affected individuals in the genome
screen clearly marked this region as being very pro-
mising.
Because several disease chromosomes in our data set
carry only a portion of the conserved haplotype, geno-
typing these patients with additional markers should fur-
ther refine the localization of the CLS gene. Additional
families, of Scandinavian and non-Scandinavian descent,
with CLS are now under study, to determine wheth-
er the Norwegian CLS haplotype is shared by patients
of other backgrounds and whether evidence for locus
homogeneity or heterogeneity exists. Since significant
migrations occurred from southwestern Norway to the
Netherlands (during the 17th and 18th centuries) and
to the United States (during the 19th and 20th centuries),
the Norwegian CLS mutation may well be present in
these populations (Sharp and Krivit 1971).
The cause of cholestasis in patients with CLS is un-
known. It has been speculated both that an abnor-
mal lymphatic system serves a normal liver, with cho-
lestasis arising secondarily (Sigstad et al. 1970) and,
alternatively, that both bile ducts and lymphatic vessels
develop abnormally in CLS (Shneider 1999). Although
lymphedema progresses with age in patients with CLS,
cholestasis decreases (Aagenaes 1998); the liver in pa-
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tients with CLS may become able to compensate for the
CLS defect as the patient matures. (A study of liver bi-
opsy specimens, obtained at different ages, from most
of the Norwegian patients is under way and may provide
insight.) Because it is difficult to predict what type of
protein the gene altered in CLS will encode and numer-
ous genes lie within the CLS interval, further refinement
of the CLS gene location will greatly facilitate its
identification.
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